Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI boosts skin diagnosis accuracy in small trial

NCT ID NCT07428954

Diagnosis Sponsor: AI Labs Group S.L Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study tested whether an AI device could help 16 doctors (10 general practitioners and 6 dermatologists) more accurately diagnose 13 different skin conditions, including melanoma, psoriasis, and acne. The doctors reviewed 29 medical images, first giving a diagnosis on their own, then seeing the AI's top five suggestions before making a final decision. The goal was to see if AI support improves diagnostic accuracy and reduces the need for specialist referrals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based medical device (computer-aided diagnosis software)
What this could lead to
If successful, this AI tool could help general doctors diagnose skin conditions more accurately, reducing unnecessary specialist referrals and speeding up treatment.
What could go wrong
This was a small, completed study with only 16 doctors and 29 images. Real-world results may differ, and the AI may not work as well on diverse skin types or in busy clinics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

16 people

The number who actually took part.

Started

Jun 2024

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of board-certified healthcare professionals recruited from the clinical fields of general medicine and dermatology. The participant group includes: * Primary Care Practitioners: General practitioners who often serve as the first point of contact for patients with dermatological symptoms. * Specialist Dermatologists: Physicians with advanced expertise in skin pathologies and rare conditions. * Experience Level: The cohort includes practitioners with at least 5 years of clinical experience in their respective specialities. Participants were recruited to engage in a remote, web-based evaluation environment rather than being selected from a single physical hospital or town. The clinical images evaluated as part of the study "cases" were sourced from international public dermatology atlases and existing research databases from the sponsor, representing a diverse global patient population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified primary care practitioners and dermatologists, regardless of their professional experience. * High-quality images of patients with different skin conditions. Exclusion Criteria: * Low-quality images of patients which can not be properly analyzed.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris alopecia decubitus ulcer dermatitis granuloma annulare herpes simplex infectious disease melanocytic nevus melanoma psoriasis seborrheic keratosis skin disorder Tinea tinea infection urticaria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne Alopecia Dermatitis Granuloma annulare Herpes Melanoma (skin cancer) Nevus Onychomychosis Pressure ulcer (PU) Psoriasis Seborrheic keratoses Tinea Urticaria

Contacts and locations

Locations

  • AI Labs Group S.L.

    Bilbao, Basque Country, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.